Bli medlem
Bli medlem

Du är här


Infant Bacterial Therapeutics AB: IBT to present at 9th Annual Biotech Showcase 2017

Infant Bacterial Therapeutics AB (publ) ("IBT"), a pharmaceutical company that
develops drugs that meet the medical needs of premature infants, will present
the company on Wednesday January 11, 2017 at the Biotech Showcase 9thAnnual
Conference at the Hilton San Francisco Union Square, 333 O'Farrell St, San
Francisco. The conference takes place between Jan. 9-11, 2017.

Staffan Strömberg, President and Chief Executive Officer will represent the
company in the presentation scheduled to begin at 11:30 am Pacific Time.

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) ("IBT") is a pharmaceutical company
with a vision to develop drugs influencing the human infant microbiome, and
thereby prevent or treat rare diseases affecting premature infants. Using its
extensive experience in live bacterial therapeutics and its well-developed
knowledge of the action ofLactobacillus reuteri
, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing
enterocolitis ("NEC"), a fatal, rare disease that afflicts premature infants.
IBT is further pursuing a second rare disease programme for the unmet medical
need Gastroschisis-Related Intestinal Dysfunction ("GRID"), a severe disease
in infants. By developing these drugs, IBT has the potential to fulfil unmet
needs for diseases where there are currently no prevention or treatment
therapies available.

The FDA and the European Commission have granted IBT Orphan Drug Designation,
and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for
the prevention of NEC.

IBT is listed on Nasdaq First North with Erik Penser Bank as Certified

For additional information please contact

Staffan Strömberg, CEO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 8 410 145 55

PR 20161215 ENG

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Infant Bacterial Therapeutics AB via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.